Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.

http://www.wikidata.org/entity/Q38233686

about

Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: a case report and review of the literature Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.Pegvisomant in acromegaly: an update.Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas Pasireotide for the treatment of acromegaly.Current and future medical treatments for patients with acromegaly.Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.

P2860

Q28087313-E9E97AC4-9284-473A-BDBC-5FD24F3E01CC Q31144045-4EA77F14-446E-4344-97B1-3A39AB4223E9 Q33725999-8BB3AAC5-F62F-431C-A6A1-447C502760FF Q35228970-23A03DBB-BE51-42C0-AE1E-80A7A16BA657 Q38710873-4184A102-2AC0-4512-88A9-5E92BD41E06E Q38847622-07000E89-C7A4-4D88-BF72-62D9F7E0B246 Q40489239-E6110B14-96FD-4641-8C0B-1F63F4EC0DE9 Q50079728-9836E5BA-45EA-43DA-BC3D-D59C1601AF2E Q51170240-F2FFE3D0-DCD1-429D-A262-AF4E11911988

P2860

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.

http://www.wikidata.org/entity/Q38233686

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Investigational drugs targetin ...... aly and neuroendocrine tumors.

@en

type

label

Investigational drugs targetin ...... aly and neuroendocrine tumors.

@en

prefLabel

Investigational drugs targetin ...... aly and neuroendocrine tumors.

@en

P1433

Q38233686-ECBB4B5A-1F48-4FEF-A3C4-538EEBC1DA30

P1476

Q38233686-1BBAB090-CA92-40FA-9102-DFD615098ADE

P2093

Q38233686-5192C753-12CF-4C6F-A8F0-2959B9EE42E1

Q38233686-A711BA54-63F1-47FA-B23A-811D90A7B369

Q38233686-DF88B2B0-AAF1-477F-ACCC-5384454BA7BD

P2860

Q38233686-000AFEA6-62E7-4530-A05C-7403AE6BAA88

Q38233686-00D1C516-2BCD-461E-A0B6-DAA472EF4865

Q38233686-01F38BB2-81C4-4116-8ABE-D399B4DE0379

Q38233686-03794D91-2996-4930-A5FF-F6D02EBC4ED3

Q38233686-03AD5999-1F50-47AA-A900-14680896CA45

Q38233686-03C7D3E2-720A-4457-A8CC-4617B0B81466

Q38233686-06FACA26-B498-49E9-8CB7-70A0F5CFF845

Q38233686-0946B503-F707-4DA5-8845-DCC9795DD5A1

Q38233686-0C340E0E-EF0C-41C1-96C5-1353B42DADDC

Q38233686-10423208-2411-4404-8EC7-B30E994AE5FC

P304

Q38233686-D3072699-BF81-4955-853A-8A0F5FD53B93

P31

Q38233686-BBE03B55-E1F1-4C43-88A8-89A5C4AD937A

P356

Q38233686-D14A1BD7-B5AB-4217-ADAE-06CC2A8E9900

P407

Q38233686-F8B48F5B-B4BC-4698-BDE2-57CC4542D8AE

P433

Q38233686-1CC94C7D-E2A3-486D-9080-E5D53CCFD4F8

P478

Q38233686-81D82311-8D7E-487F-BBFD-2E218169B86B

P50

Q38233686-A6460586-8983-40A2-9A33-E2FA9BCDEBCD

Q38233686-BC8636E0-5CA2-4BD4-A4A6-E6E47865E336

P577

Q38233686-B1CCA0B4-15EA-45E7-8EDC-096725124523

P698

Q38233686-422FDAB3-948D-4FD2-9911-F04BB17ECCCE

P356

13543784.2014.942728

P1433

Expert Opinion on Investigational Drugs

P1476

Investigational drugs targetin ...... galy and neuroendocrine tumors

@en

P2093

Alfredo Berruti

http://www.w3.org/2001/XMLSchema#string

Andrea Giustina

http://www.w3.org/2001/XMLSchema#string

Filippo Maffezzoni

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Cushing disease: overview and recent findings

Pituitary somatostatin receptor signaling

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

Somatostatin and its receptor family

Gastroenteropancreatic neuroendocrine tumours

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

P304

1619-1635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.942728

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Gherardo Mazziotti

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25060168

http://www.w3.org/2001/XMLSchema#string